Journal of geriatric oncology最新文献

{"title":"Nursing practice in cancer treatment decision making among older adults: A scoping review on behalf of the International Society of Geriatric Oncology Nursing, Allied Health, and Scientists Interest Group","authors":"Fay J. Strohschein ,&nbsp;Hanneke van der Wal-Huisman ,&nbsp;K. Alix Hayden ,&nbsp;Kristen R. Haase ,&nbsp;Michelle Hannan ,&nbsp;Cindy Kenis ,&nbsp;Juan Li ,&nbsp;Nikita Nikita ,&nbsp;Sophie Pilleron ,&nbsp;Tracy Ruegg ,&nbsp;Heike Schmidt ,&nbsp;Anke Steckelberg ,&nbsp;Cassandra Vonnes ,&nbsp;Martine Puts","doi":"10.1016/j.jgo.2026.102906","DOIUrl":"10.1016/j.jgo.2026.102906","url":null,"abstract":"<div><h3>Introduction</h3><div>Cancer treatment decision making (CTDM) presents important challenges among older adults due to variation in health and functional status, presence of comorbidities, differing goals/values, quality and quantity of life considerations, and limited inclusion in clinical trials. Nursing standards and guidelines call for competence in supporting CTDM and nurses advocate for greater involvement. However, clear understanding of the existing evidence to inform nursing practice is lacking.</div><div>We aimed to map and synthesize evidence that provides insight into nursing practice in CTDM among older adults, with attention to nursing roles, required skills and competencies, potential barriers and facilitators, and outcomes studied.</div></div><div><h3>Materials and Methods</h3><div>Following JBI (formerly Joanna Briggs Institute) methodology for scoping reviews, we included empirical articles that describe nursing contribution, individually or as part of a multidisciplinary team (MDT), related to CTDM for active (curative or non-curative) treatment among adults aged ≥60 years diagnosed with cancer. Nine databases were searched systematically from inception to January 2024, no limits applied. Two independent reviewers screened identified records and full texts, then systematically extracted data from included articles. Basic qualitative content analysis was conducted on charted data.</div></div><div><h3>Results</h3><div>Of the 9582 records screened, 980 full texts were assessed for eligibility; 84 reports describing 78 studies were included. Conducted primarily in the United States or United Kingdom, studies described nursing interventions, nursing involvement in geriatric assessment and MDT meetings/clinics, and the perspectives of patients, family, and/or healthcare professionals. Although seldom the primary focus, researchers have highlighted the important roles of nurses in the CTDM process, before, during, and after consultations with physicians and MDT meetings, which require disease-specific knowledge and relational skills. MDT collaboration, training, dedicated time and space, adequate resources, and support from leadership are critical to promoting involvement, with potential impact on decision satisfaction and optimal treatment decisions. The value of nurses' involvement is endorsed by patients, family, and other healthcare professionals.</div></div><div><h3>Discussion</h3><div>Nurses play a vital role in CTDM among older adults, particularly in the MDT context. However, rigorous studies demonstrating the impact of nursing practice on CTDM outcomes among older adults are lacking. Further research is needed to inform nursing practice and interventions.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 3","pages":"Article 102906"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147348393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers and facilitators of deprescribing for older adults with cancer and polypharmacy","authors":"Kofi Gyasi Agyei ,&nbsp;Arul Malhotra ,&nbsp;Sally A. Norton ,&nbsp;Mostafa Mohamed ,&nbsp;Katherine M. Juba ,&nbsp;Supriya Mohile ,&nbsp;Erika Ramsdale","doi":"10.1016/j.jgo.2026.102933","DOIUrl":"10.1016/j.jgo.2026.102933","url":null,"abstract":"<div><h3>Introduction</h3><div>Polypharmacy affects up to 93% of older adults with cancer and increases risks of treatment toxicity, drug interactions, and adverse outcomes. Deprescribing, the planned discontinuation of potentially inappropriate medications, can mitigate these risks. However, deprescribing interventions in oncology clinics remain understudied outside palliative care settings. This study aimed to identify barriers and facilitators to deprescribing in the oncology clinic across multiple stakeholder groups.</div></div><div><h3>Materials and methods</h3><div>Between November 2020 and August 2021, virtual focus groups were conducted with five key informant groups: patients (<em>n</em> = 9), primary care physicians (<em>n</em> = 7), oncology pharmacists (n = 7), oncology nurses (n = 7), and oncologists (<em>n</em> = 6). Participants were recruited from the University of Rochester Wilmot Cancer Institute, affiliated sites, and a patient advisory board. Semi-structured interview guides explored topics including polypharmacy definitions, medication communication, workflows, and deprescribing strategies. Sessions were audio-recorded, transcribed verbatim, and analyzed using inductive content analysis with MAXQDA software. Two coders performed open coding and developed themes categorized at patient, healthcare provider, and system levels.</div></div><div><h3>Results</h3><div>At the patient level, barriers included resistance to change, lack of awareness, mistrust, and health complexity, while facilitators included education/empowerment, effective communication, and caregiver involvement. At the provider level, barriers encompassed knowledge gaps, scope of practice concerns, and time limitations, with facilitators including inter-provider communication, education, longitudinal approaches, and provider maturity. System-level barriers included care fragmentation, electronic health record limitations, and automated workflows, while facilitators emphasized team-based care, decision support tools, and pharmacist integration. Notably, all groups expressed consistent enthusiasm for pharmacist involvement in deprescribing interventions.</div></div><div><h3>Discussion</h3><div>This analysis revealed multilevel barriers and facilitators to deprescribing in older adults with cancer. Mismatches between provider perceptions and patient attitudes suggest opportunities for improved communication. Time constraints and scope of practice concerns were prominent provider barriers, addressable through longitudinal approaches and team-based models. The consistent enthusiasm across all stakeholder groups for pharmacist-led interventions informed the design of a subsequent cluster-randomized trial. These findings suggest scalable interventions leveraging pharmacist expertise and decision support tools to address polypharmacy in this vulnerable population.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 3","pages":"Article 102933"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147365372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Geriatric assessment practices in oncology: A survey of Australian clinicians","authors":"Antonina Obayo ,&nbsp;Francine Antoinette Ocampo ,&nbsp;Baldwin Lau ,&nbsp;Samantha Bowyer ,&nbsp;Christopher Etherton-Beer ,&nbsp;Rosemary Saunders ,&nbsp;Heather Lane","doi":"10.1016/j.jgo.2026.102927","DOIUrl":"10.1016/j.jgo.2026.102927","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 3","pages":"Article 102927"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Geriatric assessment is the future: Retiring Karnofsky and ECOG performance status in modern cancer care","authors":"Stuart M. Lichtman","doi":"10.1016/j.jgo.2026.102934","DOIUrl":"10.1016/j.jgo.2026.102934","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 3","pages":"Article 102934"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147372396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75 years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailty","authors":"Patrick M. Reagan ,&nbsp;Allison Magnuson ,&nbsp;Craig A. Portell ,&nbsp;Andrea Baran ,&nbsp;Carla Casulo ,&nbsp;Alyssa R. Williams ,&nbsp;Danielle S. Wallace ,&nbsp;Paul M. Barr ,&nbsp;Jonathan W. Friedberg","doi":"10.1016/j.jgo.2026.102932","DOIUrl":"10.1016/j.jgo.2026.102932","url":null,"abstract":"<div><h3>Introduction</h3><div>Dose attenuated rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-miniCHOP) is a curative-intent regimen that balances safety and efficacy in older patients with diffuse large B-cell lymphoma (DLBCL). Incorporation of targeted agents into this backbone and the use of geriatric assessments (GA) are research priorities. Brentuximab vedotin (BV) is an anti-CD30 antibody drug conjugate that is active in DLBCL and has been safely combined with chemoimmunotherapy in younger patients. We conducted a feasibility study of BV in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-miniCHP), integrating GA and frailty assessment to describe the physiologic health of the cohort.</div></div><div><h3>Materials and methods</h3><div>Patients aged 75 years and older with DLBCL were treated with six cycles of BV and R-miniCHP. All patients underwent GA at screening, following prephase and at the end of treatment. Frailty was determined using the Deficit Accumulation Frailty Index (DAFI) using clinical and GA variables. The primary feasibility endpoint was the treatment completion rate. Secondary endpoints included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and complete response (CR). Exploratory endpoints included PFS, OS, ORR, and CR by CD30 status, and PFS and OS by DAFI score.</div></div><div><h3>Results</h3><div>We enrolled 22 patients with a median age of 77.5 years (range 75–91). Seventeen patients (77.3%) completed six cycles of BV-R-miniCHP. The ORR was 85.7% (71.4% CR). With a median follow up of 4.3 years, the median PFS was not reached and the two-year PFS was 63.6% (90% CI = 44.3%, 77.8%). There was no difference in response, or survival by CD30 status.</div><div>All 22 patients completed components of the baseline GA. There was no difference in two-year PFS (non-frail 50.0% (90% CI =23.0%, 72.1%) vs prefrail/frail 75.0% (90% CI = 47.4%, 89.5%), <em>p</em> = 0.49) or OS (non-frail 50.0% (90% CI = 23.0%, 72.1%) vs prefrail/frail 83.3% (90% CI =55.7%, 94.5%), <em>p</em> = 0.22) based on frailty as measured by DAFI score.</div><div>Hematologic toxicities and infections were the most common grade ≥ 3 adverse events. Ten patients (45%) reported a total of 16 serious adverse events. There were two deaths during treatment.</div></div><div><h3>Discussion</h3><div>Incorporation of GA and BV R-miniCHP is feasible in untreated, older adults with DLBCL.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 3","pages":"Article 102932"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147372398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of frailty on early postoperative outcomes of lobectomy for lung cancer in older adults – A United States National Retrospective Cohort Study","authors":"Diana Barragan-Bradford ,&nbsp;Ruben Oganesyan ,&nbsp;Alexander Nagrebetsky ,&nbsp;Omar Hyder","doi":"10.1016/j.jgo.2026.102920","DOIUrl":"10.1016/j.jgo.2026.102920","url":null,"abstract":"<div><h3>Introduction</h3><div>Pulmonary lobectomy represents the primary curative treatment for lung cancer in older adults, yet frailty's impact on critical early postoperative outcomes remains inadequately characterized. This analysis examined the effect of preoperative frailty on early postoperative mortality and failure-to-rescue in a contemporary national cohort.</div></div><div><h3>Materials and methods</h3><div>This retrospective cohort study analyzed older adults undergoing pulmonary lobectomy for lung cancer using the National Inpatient Sample (2016–2022). The Johns Hopkins Adjusted Clinical Groups (ACG) frailty indicator and Hospital Frailty Risk Score (HFRS) were used to identify frail patients. Multivariable logistic regression examined associations between frailty and failure-to-rescue (death after postoperative complications) and 14-day in-hospital mortality.</div></div><div><h3>Results</h3><div>Among 110,460 patients aged ≥65 years, frailty prevalence was 5.7% (<em>n</em> = 6290) by ACG indicator and 19.8% (<em>n</em> = 21,915) by HFRS (≥5). Among ACG-defined frail patients, the most common frailty-defining conditions were dementia (37.8% of frail patients), malnutrition (36.0%), and weight loss (11.6%). Overall complication rate was 39.3%, but frail patients (HFRS ≥5) experienced higher rates (69.0% versus 32.0%), higher hospitalization costs (median $104,446 versus $88,532), and reduced likelihood of home discharge (83.3% versus 95.5%; all <em>p</em> &lt; 0.001). Overall 14-day mortality was 0.8%. Frail patients had higher rates of failure-to-rescue (ACG: 3.7% versus 1.7%; HFRS: 4.1% versus 0.8%) and mortality (ACG: 2.1% versus 0.7%; HFRS: 2.8% versus 0.3%; all <em>p</em> &lt; 0.001) compared with non-frail patients. After multivariable adjustment, frailty remained associated with failure-to-rescue (ACG: OR 2.01, 95% CI 1.36–3.06; HFRS: OR 4.66, 95% CI 3.27–6.63) and 14-day mortality (ACG: OR 2.70, 95% CI 1.77–4.10; HFRS: OR 9.30, 95% CI 6.52–13.26). Frailty accounted for 68% of early deaths within the frail cohort and 11% of all cohort deaths.</div></div><div><h3>Discussion</h3><div>Preoperative frailty was associated with early postoperative mortality and failure-to-rescue rates following pulmonary lobectomy in older adults, emphasizing the need for systematic frailty assessment, enhanced perioperative surveillance, and targeted interventions for this population.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 3","pages":"Article 102920"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147317370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter to the editor: “Cardiovascular and cancer-specific mortality in older patients with advanced non-small cell lung cancer following the introduction of immuno-oncology therapies”","authors":"Yeijin Kim ,&nbsp;Jiyeon Lee ,&nbsp;Hae Sun Suh ,&nbsp;Chanhyun Park","doi":"10.1016/j.jgo.2026.102928","DOIUrl":"10.1016/j.jgo.2026.102928","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 3","pages":"Article 102928"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147458144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individualized physical activity program for older adults undergoing chemotherapy for hematologic malignancies","authors":"Baptiste Fournier ,&nbsp;Chiara Russo ,&nbsp;Aurélia Maire ,&nbsp;Romain Buono ,&nbsp;Laure Lebras ,&nbsp;Yann Guillermin ,&nbsp;Clémence Santana ,&nbsp;Philippe Rey ,&nbsp;Amine Belhabri ,&nbsp;Anne-Sophie Michallet ,&nbsp;Lucie Jauffret ,&nbsp;Emilie Pretet-Flamand ,&nbsp;Catherine Terret ,&nbsp;Mauricette Michallet ,&nbsp;Béatrice Fervers ,&nbsp;Emmanuelle Nicolas-Virelizier ,&nbsp;Olivia Pérol","doi":"10.1016/j.jgo.2026.102901","DOIUrl":"10.1016/j.jgo.2026.102901","url":null,"abstract":"<div><h3>Introduction</h3><div>Older adults with hematologic malignancies are at high risk of treatment-related functional decline. Although physical activity (PA) may mitigate these effects, evidence in older adults with acute myeloid leukemia (AML) and non-Hodgkin lymphoma (NHL) remains limited. We evaluated the feasibility and exploratory effects of a 6-month individualized PA program delivered during and after chemotherapy in this population.</div></div><div><h3>Material and methods</h3><div>The OncoGeriatric and Individualized Physical Activity (OCAPI) study is a single-arm, prospective feasibility study evaluating a 6-month individualized PA program in AML/NHL patients ≥65 years receiving chemotherapy <em>±</em> immunotherapy. The PA program included supervised and unsupervised sessions, an activity tracker, and motivational phone calls. The primary outcome was progam adherence. Secondary outcomes were feasibility metrics (recruitment, retention, adherence, safety, and patient satisfaction) assessed throughout the study, and exploratory effectiveness measures (physical condition, PA behavior, and patient-reported and geriatric outcomes) evaluated at baseline, three, and six months.</div></div><div><h3>Results</h3><div>Forty-two participants were enrolled. Rates of recruitment and retention were 59% and 88%, respectively. Adherence was 66% for supervised sessions, and &lt; 5% for unsupervised ones. Activity trackers were worn 63% of the prescribed time and 75% of scheduled calls were completed. No exercise-related adverse events occurred. Patient satisfaction was high (96%). Perceived usefulness was 91% for supervised sessions, 54% for unsupervised sessions, 84% for the activity tracker, and 86% for motivational calls. At three months, in the overall cohort, handgrip strength showed a decline and balance an improvement, but there were no changes in other performance, patient-reported, or geriatric outcomes. Changes in limb strength and walking endurance may varied by diagnosis, with NHL patients tending to improve, and AML ones tending to decline. At six months, among all participants, walking endurance improved significantly and clinically (+53 m in the 6-Minute Walk Test, <em>p</em> = 0.01), while left-hand grip strength declined. Nutritional status and quality of life also showed improvement, with no notable changes in other outcomes.</div></div><div><h3>Discussion</h3><div>The individualized PA program was feasible and safe for older patients with AML/NHL during chemotherapy. Exploratory effectivenness findings suggest that patients improved walking endurance and quality of life and diagnosis-specific functional trajectories. Larger multicenter trials are needed to confirm these preliminary observations.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 3","pages":"Article 102901"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146154195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Geriatric oncology in 2040: Exploring potential realities and challenges. A diverse perspective","authors":"Raymond Gardner ,&nbsp;Luciola Pontes Leite de Barros ,&nbsp;Kwok Leung Cheung ,&nbsp;William Dale ,&nbsp;Lore Decoster ,&nbsp;Barbara Ewals ,&nbsp;Cindy Kenis ,&nbsp;Martine Puts ,&nbsp;Christopher Steer ,&nbsp;Hans Wildiers ,&nbsp;Grant Williams ,&nbsp;Nicolò Matteo Luca Battisti","doi":"10.1016/j.jgo.2026.102907","DOIUrl":"10.1016/j.jgo.2026.102907","url":null,"abstract":"<div><div>The average global life expectancy is predicted to increase to approximately 80 years by 2040 [<span><span>1</span></span>]. Cancer is an ageing-related disease, and its prevalence will also increase with this ageing of the population [<span><span>2</span></span>]. This rise in older adults living with cancer will demand innovation in service delivery, multidisciplinary collaboration, and a renewed focus on compassionate, patient-centred care. We are therefore compelled to rethink how we approach cancer diagnosis, treatment, and survivorship. This white paper explores the potential realities and challenges through a multidimensional lens, addressing the intersection of demographic shifts, rapid technological advancements, and the evolving needs of older adults living with cancer. Key areas examined include the integration of precision medicine and digital health tools, the adaptation of healthcare delivery models, and the implications for workforce training and resource allocation.</div><div>The discussion highlights disparities in care, the importance of personalised interventions, and strategies to enhance quality of life for older adults with cancer. By anticipating these developments, the paper offers critical insights for policymakers (who set the rules and goals and allocate funding), health system leaders (who manage the day-to-day operations), clinicians and allied health professionals (who are patient-facing), and patients and caregivers, aiming to promote equity, innovation, quality and resilience in the care of older adults with cancer as we approach the next decade.</div><div>The paper seeks to consolidate and clarify the diverse issues and opportunities that will emerge as the global population ages and the burden of cancer among older adults rises. With average life expectancy predicted to approach 80 years by 2040, and cancer recognised as a disease closely linked to ageing [<span><span>3</span></span>], the paper brings together expert perspectives to provide a sector-wide synthesis of the impending challenges. Its purpose is not to offer a conventional systematic review, but rather to serve as a strategic resource for policymakers, health system leaders, clinicians, allied health professionals, patients, and caregivers, informing the response to demographic shifts, technological advances and evolving patient needs. By consolidating insights on disparities in care, the necessity for personalised interventions, and strategies to enhance quality of life, the paper aims to inform and inspire innovation, equity and resilience in geriatric oncology as we approach the next decade.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 3","pages":"Article 102907"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147317419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor: Cardiovascular and cancer-specific mortality in older patients with advanced non-small cell lung cancer following the introduction of immuno-oncology therapies","authors":"Sari Luthfiyah ,&nbsp;Ach. Arfan Adinata ,&nbsp;Joylyn L. Mejilla ,&nbsp;Mohammed Ismath","doi":"10.1016/j.jgo.2026.102929","DOIUrl":"10.1016/j.jgo.2026.102929","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 3","pages":"Article 102929"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147365328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}